Pickcells key facts
as of Oct 2026- Developer of an AI-powered diagnostic platform designed to optimize workflows and increase accuracy across clinical and laboratory environments.
- Pickcells is valued at approximately $640K as of Oct 2026 (last reported valuation).
- It has raised $680K; the latest was Seed Round ($20K) in Dec 2024.
- Notable investors include KPTL, Artemisia, Biominas Brasil, Brazil Accelerate 2030, InovaHC.
- Status: Privately Held (backing).
Pickcells's last reported valuation, Apr 2023. Nothing priced has surfaced since.
- ·Watch Pickcells: the Monday email on marks, rounds and moves
Pickcells funding rounds
No funding rounds for Pickcells are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Pickcells
5Pickcells valuation
Pickcells's last reported valuation was $640,000 in Apr 2023. No priced round, secondary trade or fund mark has surfaced since.
Pickcells investors
5 investors are on record for Pickcells, including KPTL, Artemisia, Biominas Brasil and Brazil Accelerate 2030.
About Pickcells
Developer of an AI-powered diagnostic platform designed to optimize workflows and increase accuracy across clinical and laboratory environments. The company's platform offers automated slide analysis, cloud-based biorepositories, and integrated software-hardware systems, enabling hospitals, pathology labs, and healthcare professionals to accelerate diagnostics, reduce manual effort, and improve decision-making.
- Sector
- Healthcare
- HQ
- Recife, Brazil
- Founded
- 2014
- Employees
- 15
- Website
- pickcells.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.